| Ticker | Company | Sub-Theme | Mkt Cap▼ | Price | Chg% | Volume |
|---|---|---|---|---|---|---|
| Eli Lilly & Co. | Metabolic & Cardiometabolic | $1.0t | $1159.02 | +2.4% | 1.9M | |
| Johnson & Johnson | Immunology & Autoimmune | $0.5t | $231.90 | -0.4% | 2.5M | |
| ABBVIE INC. | Immunology & Autoimmune | $384.7b | $222.33 | -2.2% | 1.7M | |
| Merck & Co., Inc. | Infectious Disease & Vaccines | $293.2b | $119.85 | -0.8% | 3.1M | |
| AstraZeneca PLC | Metabolic & Cardiometabolic | $287.9b | $183.68 | -1.2% | 1.0M | |
| Thermo Fisher Scientific, Inc. | Clinical-Stage Platforms | $183.0b | $471.65 | -0.2% | 517.5K | |
| Amgen Inc | Immunology & AutoimmuneRare Disease Therapeutics | $181.8b | $345.87 | -1.1% | 726.4K | |
| Gilead Sciences Inc | Infectious Disease & Vaccines | $166.9b | $127.69 | -1.1% | 2.2M | |
| Pfizer Inc. | Infectious Disease & Vaccines | $149.2b | $25.80 | -0.9% | 15.7M | |
| Bristol-Myers Squibb Co. | Immunology & Autoimmune | $116.8b | $56.28 | -1.7% | 4.6M | |
| Vertex Pharmaceuticals Inc | Rare Disease Therapeutics | $113.6b | $446.12 | -0.2% | 302.3K | |
| Regeneron Pharmaceuticals Inc | Immunology & Autoimmune | $64.5b | $617.68 | -2.8% | 235.2K | |
| Alnylam Pharmaceuticals, Inc. | Rare Disease Therapeutics | $40.3b | $290.84 | -4.0% | 657.7K | |
| Agilent Technologies Inc. | Clinical-Stage Platforms | $38.2b | $133.43 | -1.5% | 368.2K | |
| Waters Corp | Clinical-Stage Platforms | $37.7b | $364.45 | -0.2% | 203.2K | |
| IQVIA Holdings Inc. | Clinical-Stage Platforms | $30.4b | $182.31 | -0.6% | 247.8K | |
| Biogen Inc. Common Stock | Neuroscience & CNS | $28.9b | $194.43 | -0.5% | 361.4K | |
| Royalty Pharma plc Class A Ordinary Shares | Clinical-Stage Platforms | $24.7b | $55.64 | -0.4% | 1.4M | |
| United Therapeutics Corp | Rare Disease Therapeutics | $23.6b | $548.00 | -0.3% | 129.4K | |
| Insmed, Inc. | Rare Disease Therapeutics | $23.2b | $95.23 | +1.1% | 2.1M | |
| West Pharmaceutical Services, Inc. | Clinical-Stage Platforms | $22.8b | $318.79 | +1.4% | 109.3K | |
| Roivant Sciences Ltd. Common Shares | Immunology & Autoimmune | $21.6b | $28.63 | +0.2% | 1.3M | |
| Incyte Genomics Inc | Rare Disease Therapeutics | $19.3b | $101.05 | -1.3% | 983.8K | |
| Moderna, Inc. Common Stock | Infectious Disease & Vaccines | $18.7b | $47.88 | +0.9% | 1.6M | |
| Neurocrine Biosciences Inc | Neuroscience & CNS | $15.9b | $163.59 | -0.2% | 193.1K | |
| Jazz Pharmaceuticals, Inc. | Neuroscience & CNS | $14.8b | $235.03 | -1.5% | 464.4K | |
| Ascendis Pharma A/S Ordinary Share | Clinical-Stage Platforms | $13.8b | $205.65 | -2.3% | 191.4K | |
| Summit Therapeutics Inc. Common Stock | Infectious Disease & Vaccines | $13.6b | $14.41 | -2.4% | 1.4M | |
| BridgeBio Pharma, Inc. Common Stock | Rare Disease Therapeutics | $13.0b | $67.78 | +0.2% | 411.8K | |
| Medpace Holdings, Inc. Common Stock | Clinical-Stage Platforms | $12.8b | $455.67 | +0.3% | 60.5K | |
| Ionis Pharmaceuticals, Inc. Common Stock | Rare Disease Therapeutics | $12.6b | $73.97 | -0.7% | 469.2K | |
| Axsome Therapeutics, Inc | Neuroscience & CNS | $12.1b | $237.79 | +2.4% | 199.0K | |
| Regencell Bioscience Holdings Limited Ordinary Shares | Neuroscience & CNS | $11.8b | $21.50 | +7.6% | 56.8K | |
| Revvity, Inc. | Clinical-Stage Platforms | $11.7b | $101.13 | +2.8% | 420.2K | |
| Madrigal Pharmaceuticals, Inc. Common Stock | Metabolic & Cardiometabolic | $11.5b | $474.21 | -2.6% | 81.2K | |
| BioMarin Pharmaceuticals Inc | Rare Disease Therapeutics | $11.1b | $56.25 | -0.9% | 399.3K | |
| Arrowhead Research Corporation | Rare Disease Therapeutics | $11.0b | $73.77 | +0.9% | 355.0K | |
| Cytokinetics Inc. | Rare Disease TherapeuticsNeuroscience & CNS | $10.4b | $69.27 | -3.1% | 700.9K | |
| Icon Plc | Clinical-Stage Platforms | $10.4b | $151.49 | +1.4% | 363.0K | |
| Praxis Precision Medicines, Inc. Common Stock | Neuroscience & CNS | $9.8b | $257.17 | +1.2% | 236.6K | |
| Krystal Biotech, Inc. Common Stock | Rare Disease Therapeutics | $9.1b | $304.68 | +1.2% | 61.7K | |
| Bruker Corporation | Clinical-Stage Platforms | $9.0b | $57.03 | +1.1% | 811.6K | |
| Charles River Laboratories International, Inc. | Clinical-Stage Platforms | $8.7b | $184.04 | +1.5% | 222.2K | |
| Bio-Rad Laboratories, Inc. Class B | Clinical-Stage Platforms | $8.1b | $306.58 | +0.8% | 2 | |
| Bio-Techne Corp. | Clinical-Stage Platforms | $8.1b | $53.05 | +2.0% | 1.4M | |
| Halozyme Therapeutics, Inc. | Clinical-Stage Platforms | $7.9b | $71.55 | +0.0% | 535.5K | |
| ImmunityBio, Inc. Common Stock | Immunology & Autoimmune | $7.9b | $7.14 | +3.2% | 5.4M | |
| QIAGEN N.V. | Clinical-Stage Platforms | $7.5b | $36.47 | -0.6% | 550.0K | |
| Corcept Therapeutics Inc. | Rare Disease Therapeutics | $7.5b | $74.85 | +3.1% | 244.6K | |
| Vaxcyte, Inc. Common Stock | Infectious Disease & Vaccines | $7.4b | $46.25 | -2.3% | 264.2K |